2016
The Efficacy of Bisphosphonates with Core Decompression and Mesenchymal Stem Cells Compared with Bisphosphonates Alone in the Treatment of Osteonecrosis of the Hip: A Retrospective Study
Gianakos A, Moya-Angeler J, Duggal S, Zambrana L, Fields K, Mintz D, Cornell C, Lane J. The Efficacy of Bisphosphonates with Core Decompression and Mesenchymal Stem Cells Compared with Bisphosphonates Alone in the Treatment of Osteonecrosis of the Hip: A Retrospective Study. HSS Journal ® 2016, 12: 137-144. PMID: 27385942, PMCID: PMC4916091, DOI: 10.1007/s11420-016-9487-7.Peer-Reviewed Original ResearchModified Harris Hip ScoreVisual analogue scoreTotal hip arthroplastyBisphosphonate therapyCore decompressionMesenchymal stem cellsFunctional outcomeTreatment groupsHip replacementFemoral headEfficacy of bisphosphonatesFicat stage IRadiologic outcome measuresHarris hip scoreYear of diagnosisTreatment of osteonecrosisFuture prospective studiesEarly-stage ONFHInclusion/exclusion criteriaStem cellsJoint preserving proceduresTotal hip replacementProgression of collapseFicat stageInstitution's registry
2015
Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday
Villa J, Gianakos A, Lane J. Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday. HSS Journal ® 2015, 12: 66-73. PMID: 26855630, PMCID: PMC4733702, DOI: 10.1007/s11420-015-9469-1.Peer-Reviewed Original ResearchRecent fragility fractureDrug holidayBisphosphonate treatmentFragility fracturesBone deficiencyQuestions/PurposesThe purposeHigh fracture riskBone turnover rateRisk of fractureBone mass measurementsBisphosphonate therapyDrug discontinuationPeer-reviewed journalsCase seriesDrug therapyFracture riskPurposesThe purposeClinical trialsInclusion criteriaCase controlExclusion criteriaMethodsA reviewHuman studiesPatientsElectronic databases